Aldeyra Therapeutics Inc’s filing revealed that its Chief Development Officer Machatha Stephen unloaded Company’s shares for reported $75975.0 on Aug 12 ’24. In the deal valued at $4.74 per share,16,041 shares were sold. As a result of this transaction, Machatha Stephen now holds 236,771 shares worth roughly $1.5 million.
Then, Greenberg Bruce sold 10,834 shares, generating $51,313 in total proceeds. Upon selling the shares at $4.74, the insider now owns 126,382 shares.
Before that, Greenberg Bruce bought 10,834 shares. Aldeyra Therapeutics Inc shares valued at $55,253 were divested by the Officer at a price of $5.10 per share.
Oppenheimer upgraded its Aldeyra Therapeutics Inc [ALDX] rating to an Outperform from a a Perform in a research note published recently. H.C. Wainwright started covering the stock on February 08, 2021. It rated ALDX as “a Buy”.
Price Performance Review of ALDX
On Friday, Aldeyra Therapeutics Inc [NASDAQ:ALDX] saw its stock jump 0.95% to $6.35. Over the last five days, the stock has gained 24.27%. Aldeyra Therapeutics Inc shares have risen nearly 27.25% since the year began. Nevertheless, the stocks have risen 61.58% over the past one year. While a 52-week high of $6.92 was reached on 02/18/25, a 52-week low of $2.71 was recorded on 01/13/25. SMA at 50 days reached $5.58, while 200 days put it at $4.93.
Levels Of Support And Resistance For ALDX Stock
The 24-hour chart illustrates a support level at 6.15, which if violated will result in even more drops to 5.95. On the upside, there is a resistance level at 6.58. A further resistance level may holdings at 6.81. The Relative Strength Index (RSI) on the 14-day chart is 55.70, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.08, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 26.64%. Stochastics %K at 69.31% indicates the stock is a holding.
The most recent change occurred on December 16, 2020 when Berenberg began covering the stock and recommended ‘”a Buy”‘ rating along with a $32 price target.
